-
Mashup Score: 0ELARA trial: Does tisa-cel CAR T-cell therapy hold promise for patients with follicular lymphoma? - 3 year(s) ago
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Martin Dreyling, Ludwig-Maximilians-Universität München, Munich, DE. We asked, Does tisa-cel chimeric antigen receptor (CAR) T-cell therapy hold promise for patients with follicular lymphoma?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Differentiation syndrome with lower-intensity therapy for AML - 3 year(s) ago
Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA, discusses differentiation syndrome, a potentially fatal complication first observed…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Differentiation syndrome with lower-intensity therapy for AML, w/ Amir Fathi of @MGHCancerCenter: https://t.co/WStQDNQzJw @EHA_Hematology #EHA2021 #HemOnc #Leusm #Leukemia #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM
-
-
Mashup Score: 2
Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the rationale for a chimeric antigen receptor…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ADCLEC.SYN1: Combinatorial #CART shows preclinical potential for R/R #AML @HaubnerSascha of @sloan_kettering shares info on a CAR-T designed to target both ADGRE2 & CLEC12A: https://t.co/65r29PdLHi #EHA2021 @VJHemOnc #HemOnc #Leusm #Leukemia #CancelBloodCancer #BCAM
-
-
Mashup Score: 0The DREAMM-5 PLATFORM trial - 3 year(s) ago
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the ongoing DREAMM-5 trial (NCT04126200), a Phase I/II study designed…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Paul Richardson of @DanaFarber talks on the ongoing DREAMM-5 PLATFORM trial A Phase I/II study designed to identify effective belamaf combinations for R/R #Myeloma 👉 https://t.co/rI8eHyN2rX👈 @EHA_Hematology #EHA2021 #HemOnc #MMSM #BloodCancerAwarenessMonth #CancelBloodCancer
-
-
Mashup Score: 0EHA 2021: targeted therapies for ALL - 3 year(s) ago
Great progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 Don't miss our podcast on targeted therapies for ALL where experts discuss highlights from the #EHA2021 meeting 💉👨⚕️👩⚕️ 🎧 Listen here: https://t.co/ivp4T35OjI @VJHemOnc #VJSounds #ALLsm #LEUsm #Leukemia
-
-
Mashup Score: 0EHA 2021: updates on novel agents for AML - 3 year(s) ago
A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#VJSounds: EHA 2021: updates on novel agents for AML Catch up on the trial updates presented at the #EHA2021 meeting with experts Andrew Brunner, Mark Levis, Stéphane de Botton and Andrius Zucenka 👨⚕️👩⚕️📣 🎧 Listen now: https://t.co/kD1QiuzSsw @VJHemOnc #AMLsm #LEUsm #Leukemia
-
-
Mashup Score: 0NGS screening for novel MRD tracking markers in the FOLL12 trial - 3 year(s) ago
Simone Ferrero, MD, University of Torino, Torino, Italy, discusses the findings of next-generation sequencing (NGS) analysis in the FOLL12 trial…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Screening for novel #MRD tracking markers in FOLL12 Simone Ferrero of @unito discusses the findings of #NGS analysis in the FOLL12 trial in patients with #FollicularLymphoma: https://t.co/ogRoQmNRJp #EHA2021 #HemOnc #Lymphoma #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM
-
-
Mashup Score: 3Optimizing treatment of MCL - 3 year(s) ago
Georg Hess, MD, University Medical Center Mainz, Mainz, Germany, gives an overview of key updates in the treatment of patients…
Source: VJHemOncCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @VJHemOnc: Georg Hess of @uni_mainz_eng discusses key updates in the treatment of #MCL patients: https://t.co/frFFyXzXNy #EHA2021 #Lym…
-
Georg Hess of @uni_mainz_eng discusses key updates in the treatment of #MCL patients: https://t.co/frFFyXzXNy #EHA2021 #Lymphoma #CART #Lymsm #ImmunoOnc #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM
-
-
Mashup Score: 1SLAMF7 as a target for multiple myeloma - 3 year(s) ago
Leo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, gives an update on the role of elotuzumab,…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Leo Rasche of @uamshealth gives an update on the role of SLAMF7 as a therapeutic target in #MultipleMyeloma, including the use of elotuzumab: https://t.co/khyaCK858v #EHA2021 #HemOnc #Myeloma #MMsm #MultipleMyeloma #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM
-
-
Mashup Score: 1Recent and upcoming data on axi-cel for patients with NHL - 3 year(s) ago
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, talks on the approval of axicabtagene ciloleucel (axi-cel) for the treatment…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Recent & upcoming data on axi-cel in #NHL Ulrich Jäger of @MedUni_Wien discusses the data leading to the approval of axi-cel & continued investigations: 👉https://t.co/zYMCvZerlh👈 #EHA2021 #HemOnc #Lymsm #NHLsm #Lymphoma #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM
-
👀 During #EHA2021, we spoke with Martin Dreyling, @LMU_Muenchen, about the ELARA trial, and the latest data of tisa-cel for patients with follicular #lymphoma 📽️https://t.co/C3XE8rIySo